Rates of sustained complete renal-response with long-term use of voclosporin in AURORA 2 (UKKW 2025) - Jun 9, 2025 - Abstract #464; "Significantly more patients treated with VCS in combination with MMF and low-dose glucocorticoids (GCs) achieved CRR compared to patients in the control arm treated with mycophenolate mofetil (MMF) and low-dose GCs (41% vs 23%, odds ratio [OR] 2.65, 95% confidence interval [CI] 1.64-4.27, p<0.0001). SCRR is a novel endpoint that can be leveraged to illustrate disease trajectory of LN and treatment efficacy. Consistent with using CRR as an efficacy endpoint in AURORA 1, more VCS- than control- treated patients achieved SCRR, despite nearly 40% of the analyzed study population being ineligible due to the voluntary nature of AURORA 2 participation. The stringency and potential utility of this new endpoint require further exploration."
Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Dr Ernie Yap1; Dr Matt Truman1; Dr Cynthia Auguste1; Director Vanessa Birardi1; Dr Greg Keenan1
|